Effect of Antiretroviral Therapy Including Lopinavir/Ritonavir or Efavirenz on Etonogestrel-Releasing Implant Pharmacokinetics in HIV-Positive Women

@article{Vieira2014EffectOA,
  title={Effect of Antiretroviral Therapy Including Lopinavir/Ritonavir or Efavirenz on Etonogestrel-Releasing Implant Pharmacokinetics in HIV-Positive Women},
  author={C. Vieira and M. V. Bahamondes and R. M. de Souza and M. B. Brito and Tatiana R Rocha Prandini and E. Amaral and L. Bahamondes and G. Duarte and S. Quintana and Carolina Scaranari and R. Ferriani},
  journal={JAIDS Journal of Acquired Immune Deficiency Syndromes},
  year={2014},
  volume={66},
  pages={378–385}
}
  • C. Vieira, M. V. Bahamondes, +8 authors R. Ferriani
  • Published 2014
  • Medicine
  • JAIDS Journal of Acquired Immune Deficiency Syndromes
  • Objective:Data on the interaction between the etonogestrel (ENG) implant and antiretroviral therapy are lacking. We evaluated the effect of 2 highly active antiretroviral therapy (HAART) regimens (1 including efavirenz and the other ritonavir-boosted lopinavir) on the pharmacokinetic (PK) parameters of an ENG-releasing implant in HIV-positive women. Design:Prospective nonrandomized PK study. Methods:Forty-five HIV-positive women who desired to use ENG implants were included: 15 had received… CONTINUE READING
    59 Citations
    Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy
    • 2
    Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy
    • 28
    Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
    • 2
    Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments.
    • G. Russo, G. Paganotti, +4 authors L. Gustafsson
    • Biology, Medicine
    • Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
    • 2016
    • 15

    References

    SHOWING 1-10 OF 46 REFERENCES
    Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients
    • 65
    • PDF
    Pharmacokinetic Interactions between the Hormonal Emergency Contraception, Levonorgestrel (Plan B), and Efavirenz
    • 56
    • PDF
    Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.
    • 174
    ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
    • 403
    • PDF
    Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.
    • 405
    • PDF
    Contraception for the HIV-Positive Woman: A Review of Interactions between Hormonal Contraception and Antiretroviral Therapy
    • 80
    • Highly Influential
    • PDF